just thought I would bring this up- valuations of biotech’s fitting a pretty nifty correlation between revenue growth percentages and the revenue multiple applied. About as strong as correlations get. Ahz has 24M revenue last year. A 30% growth would apply a 4x multiplier ect;
Essentially this comes down to will the company go forward or under. If you think it will go forward it’s an easy buy, if not then why would you invest anyway. And I believe it will grow and this is just the begining. The future is definately bright
Awesome Week Ahead #awesomeweekahead, page-5
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.00 |
Change
0.000(0.00%) |
Mkt cap ! $317.0M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.00 | $14.36 | $82.01K | 5.582K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $14.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.00 | 5141 | 3 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |